FDA routes to market for drugs and biologics
A drug or biological product reaches the United States market through one of four application types. These are a full new drug application under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act, a 505(b)(2) application, an abbreviated new drug application under section 505(j) or a biologics license application under section 351 of the Public Health Service Act. The route available depends on whether the product is a biological product subject to licensure, on whether a listed drug exists that the product duplicates, and on whether the applicant conducted the investigations it relies upon. Each route carries its own content requirements, its own review clock and its own evidence standard.12
The full new drug application
A full NDA rests on investigations conducted by or for the applicant, or on investigations the applicant has a right to reference or use. Section 314.50 requires three copies of the application: an archival copy, a review copy and a field copy. An NDA for a new chemical entity generally contains the following.
- an application form
- an index
- a summary
- five or six technical sections
- case report tabulations of patient data
- case report forms
- drug samples
- labeling
The application must contain reports of all investigations of the drug product sponsored by the applicant, together with all other information about the drug pertinent to an evaluation of the NDA that the applicant receives or obtains from any source.1
Effectiveness is established through adequate and well-controlled investigations as defined in § 314.126. Such a study has a clear statement of objectives and a summary of the proposed or actual methods of analysis in the protocol and in the report of results. It uses a design permitting a valid comparison with a control to give a quantitative assessment of drug effect. Lack of substantial evidence consisting of adequate and well-controlled investigations is a ground for refusal to approve under § 314.125(b)(5). Other refusal grounds include inadequate manufacturing methods, facilities and controls, insufficient safety information and false or misleading proposed labeling.1
Section 314.90 allows an applicant to ask FDA to waive any requirement that applies under §§ 314.50 through 314.81, and to waive any criterion of an adequate and well-controlled study under § 314.126(c). The request must be submitted with supporting documentation in the NDA or in an amendment or supplement. It must explain why compliance is unnecessary or cannot be achieved, describe an alternative submission that satisfies the purpose of the requirement, or otherwise justify the waiver. A waived requirement does not constitute a basis for refusal to approve under § 314.125.1
The 505(b)(2) route
A 505(b)(2) application is an NDA submitted under section 505(b)(1) for a drug where at least some of the investigations relied upon were not conducted by or for the applicant and where the applicant has no right of reference or use. Such an application is the route for a drug product that represents a modification of a listed drug, such as a new indication or a new dosage form, where investigations other than bioavailability or bioequivalence studies are essential to approval of the change. The application need contain only the information needed to support the modification.1
Section 314.54(a)(1)(iii) requires the applicant to identify each listed drug for which FDA has made a finding of safety and effectiveness and on which the applicant relies. The identification gives the following.
- the established name
- the proprietary name
- dosage form
- strength
- route of administration
- the name of the application holder
- the approved NDA number
At least one listed drug relied upon must be pharmaceutically equivalent to the proposed product and must have been approved before the original 505(b)(2) application was submitted.1
The abbreviated route for generic drugs
Section 314.92 makes abbreviated applications suitable for drug products that are the same as a listed drug. The same means identical in active ingredients, dosage form, strength, route of administration and conditions of use. Conditions of use that cannot be approved because of exclusivity or an existing patent may be omitted. Products declared suitable by FDA through the petition procedures of § 10.30 and § 314.93 are also eligible.1
An applicant seeking approval of a product that differs from a listed drug in route of administration, dosage form or strength, or that substitutes one active ingredient in a listed combination drug, must first obtain permission through a suitability petition under § 314.93. The petition identifies a listed drug, includes the proposed labeling and the approved labeling of the listed drug, and shows that the active ingredients are of the same pharmacological or therapeutic class and that the product can be expected to have the same therapeutic effect.1
Section 314.94 sets the ANDA content. The application must refer to a listed drug, ordinarily the product selected as the reference standard for bioequivalence testing. It must name the reference listed drug with its dosage form and strength, state whether that drug is entitled to marketing exclusivity under section 505(j)(5)(F), and state that the proposed conditions of use have been previously approved for the reference listed drug. Where the listed drug has been voluntarily withdrawn from sale, § 314.122 requires an accompanying petition seeking a determination of whether the withdrawal was for safety or effectiveness reasons. Section 314.127 lists the grounds for refusing to approve an ANDA, including insufficient information that the active ingredients, route, dosage form or strength are the same as those of the reference listed drug.1
Biologics license applications
A manufacturer obtains a biologics license by submitting an application to the Director of the Center for Biologics Evaluation and Research or the Director of the Center for Drug Evaluation and Research. The application must contain data from nonclinical laboratory and clinical studies demonstrating that the manufactured product meets the prescribed requirements of safety, purity and potency. It must also include the following.
- a full description of manufacturing methods
- stability data through the dating period
- representative samples
- summaries of lot test results
- specimens of labels and containers
- the address of each location involved in manufacture
Financial certification or disclosure statements for clinical investigators under part 54 are required, as is a categorical exclusion claim or an environmental assessment. An application is not considered filed until FDA has received all pertinent information and data.2
Approval depends on the establishment as well as the product. Section 601.20 permits approval only after examination of the product and after inspection of the establishments listed in the application. One license covers all locations meeting the establishment standards identified in the approved application. Applicable requirements include the good manufacturing practice requirements in parts 210, 211, 600, 606 and 820. A license issued under § 601.4 remains valid until suspended or revoked.2
The master file limitation is a point on which biologics practice departs from drug practice. Under § 601.2(g)(1), a biologics license application may not incorporate by reference drug substance, drug substance intermediate or drug product information contained in a master file. Paragraphs (g)(2) and (3) provide the exceptions. Separate handling applies to therapeutic DNA plasmid products, therapeutic synthetic peptide products of 40 or fewer amino acids, monoclonal antibody products for in vivo use and therapeutic recombinant DNA-derived products. For those categories, the following provisions do not apply.2
- § 600.10(b) and (c)
- § 600.11
- § 600.12
- § 600.13
- § 610.53
- § 610.62
Review clocks
Section 314.100 sets an initial review cycle of 180 days from receipt of an NDA or ANDA, at the end of which FDA sends either an approval letter under § 314.105 or a complete response letter under § 314.110. That cycle may be adjusted by mutual agreement or as the result of a major amendment. Separately, § 314.101(a) gives FDA 60 days after receipt of an NDA to decide whether the application may be filed. The date of filing is 60 days after the date FDA received the application, and that date starts the 180-day filing clock under section 505(c). Where FDA refuses to file, the applicant may request an informal conference in writing within 30 days and may then have the application filed over protest.1
An ANDA is evaluated for receipt, which is a threshold determination that the application is substantially complete. An acknowledgment letter states that determination. Approximately 90 days after receipt of an application, § 314.102(c) provides an opportunity to meet with reviewing officials on progress and identified deficiencies, for all new chemical entities and major new indications.1
A complete response letter describes all specific deficiencies identified. A Class 1 resubmission starts a new two-month review cycle from the date FDA receives it, and a Class 2 resubmission starts a new six-month cycle. For biologics, § 601.3 requires the applicant either to resubmit addressing all deficiencies or to withdraw. Failure to act within one year of issuance may be treated as a request to withdraw, after which the applicant has 30 days from FDA’s written notification to explain why the application should stand.12
Patents, certifications and the date of approval
Section 314.53 requires an NDA applicant to submit patent information on the required FDA declaration form for each drug substance patent, drug product patent and method-of-use patent that claims the drug and for which a claim of infringement could reasonably be asserted. Where a 505(b)(2) or ANDA applicant submits a paragraph IV certification, notice must be sent to each patent owner and to the holder of the approved NDA, by registered or certified mail with return receipt requested or by a designated delivery service. A 505(b)(2) applicant sends the notice on or after the date of filing and not later than 20 days after the postmark on the paragraph IV acknowledgment letter. An ANDA applicant sends it on or after receipt of that letter and within the same 20-day limit.1
Section 314.107 determines the first possible date of approval for each relevant patent, and approval may be granted on the last applicable date. Approval is immediate where the relevant patent has expired or where no relevant patents exist. It is also immediate where the applicant certifies invalidity, unenforceability or non-infringement and the 45-day period under section 505(c)(3)(C) or (j)(5)(B)(iii) has expired. Where an application otherwise meets the requirements for approval but a period of exclusivity under § 314.108, orphan exclusivity under section 527, pediatric exclusivity under section 505A or exclusivity under section 505E blocks it, FDA issues a tentative approval letter. Marketing may begin only when FDA issues an approval after any further review.1
Accelerated approval and the animal rule
Sections 314.510 and 601.41 allow approval on the basis of adequate and well-controlled trials showing an effect on a surrogate endpoint reasonably likely to predict clinical benefit, or on a clinical endpoint other than survival or irreversible morbidity. Approval carries a requirement that the applicant study the product further with due diligence to verify and describe clinical benefit. Where safe use requires it, §§ 314.520 and 601.42 impose postmarketing distribution restrictions commensurate with the safety concerns. For biologics under subpart E, § 601.45 requires submission of all promotional materials intended for dissemination within 120 days after approval during the preapproval review period, and submission at least 30 days before first use thereafter.12
Sections 314.610 and 601.91 permit approval based on adequate and well-controlled animal studies where human efficacy studies would be unethical and field trials have not been feasible. FDA relies on animal evidence only where the pathophysiological mechanism is reasonably well understood and the effect is shown in more than one predictive species or in a single sufficiently characterized model. The animal endpoint must also be clearly related to the human benefit, and kinetic and pharmacodynamic data must allow selection of an effective human dose. Approval is subject to postmarketing studies when feasible and ethical, to restrictions on distribution or use where needed, and to patient labeling explaining that approval was based on animal efficacy studies.12
Pediatric evidence
Sections 314.55 and 601.27 require each application for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration to contain data adequate to assess safety and effectiveness in all relevant pediatric subpopulations. Pediatric effectiveness may be extrapolated from adequate and well-controlled adult studies where the course of the disease and the effects of the product are sufficiently similar, usually supplemented by pharmacokinetic data in pediatric patients. FDA may defer submission until after approval in adults, on a request supported by a certification of the grounds, a description of the planned studies and evidence of due diligence. Full and partial waivers are available on the grounds set out in § 601.27(c), and § 601.27(d) exempts indications for which orphan designation has been granted.12
Questions people also ask
What distinguishes a 505(b)(2) application from an ANDA? An ANDA is available for a product that is the same as a listed drug in active ingredients, dosage form, strength, route of administration and conditions of use, or for a change approved through a suitability petition under § 314.93. A 505(b)(2) application is used where investigations other than bioavailability or bioequivalence studies are essential to approval of a change from the listed drug, such as a new indication or a new dosage form. The 505(b)(2) applicant relies in part on investigations it did not conduct and for which it holds no right of reference.1
How long does FDA have to review an application? Section 314.100 provides an initial review cycle of 180 days from receipt of an NDA or ANDA, ending in an approval letter or a complete response letter. The cycle may be adjusted by mutual agreement between FDA and the applicant, or as the result of a major amendment. For NDAs, § 314.101 gives a separate 60-day period in which FDA determines whether the application may be filed.1
What happens after a complete response letter is issued? The applicant must either resubmit the application addressing all identified deficiencies or withdraw it. For drug applications, a Class 1 resubmission starts a new two-month review cycle and a Class 2 resubmission starts a new six-month cycle from the date of receipt. For biologics, FDA may treat failure to resubmit or withdraw within one year as a request to withdraw, subject to extensions that FDA will grant on any reasonable request.12
When must paragraph IV notice be sent? An ANDA applicant sends notice on or after the date it receives a paragraph IV acknowledgment letter from FDA and not later than 20 days after the postmark on that letter. A 505(b)(2) applicant sends notice on or after the date of filing described in § 314.101(a)(2) or (3), within the same 20-day limit. Notice goes to each patent owner or its designated representative and to the holder of the approved NDA for each affected drug product.1
Does an approved biologics license application cover more than one manufacturing site? One biologics license is issued to cover all locations meeting the establishment standards identified in the approved application. Each location is subject to inspection by FDA officials. A license is issued or an application approved only after inspection of the establishments listed in the application and a determination that they comply with the standards in the application and with applicable regulations.2
What triggers withdrawal of an accelerated approval for a biological product? Section 601.43 allows FDA to withdraw approval following a hearing where a postmarketing clinical study fails to verify clinical benefit, where the applicant fails to perform the required study with due diligence, or where postmarketing restrictions prove inadequate to ensure safe use. False or misleading promotional materials and failure to adhere to agreed restrictions are also grounds. An applicant who fails to file a written request for a hearing within 15 days of receiving the notice waives the opportunity for one.2
Footnotes
-
21 CFR Part 314, Applications for FDA Approval to Market a New Drug. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21
-
21 CFR Part 601, Licensing. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-601 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11
Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.